

**Biocon Limited**

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/EA/2025-26/49

June 26, 2025

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - Biocon
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI Listing Regulations.

This is to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, June 26, 2025 approved acquisition of Optionally Convertible Debentures (OCDs) of Biocon Biologics Limited, an unlisted subsidiary of the Company, from Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 and Goldman Sachs India AIF Scheme-1 (“Goldman Sachs”).

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, please find enclosed the disclosure w.r.t. the proposed acquisition of OCDs of Biocon Biologics Limited pursuant to the agreement, as amended, entered into between the Company and Goldman Sachs, whereby the proposed acquisition was subject to approval of the Board.

The above-mentioned information will also be available on the website of the Company at www.biocon.com.

The Board Meeting commenced at 6:00 PM and concluded at 6:10 PM.

Kindly take the above information on record and acknowledge.

Thanking You,

For **Biocon Limited**

Siddharth Mittal
Managing Director & CEO
DIN: 03230757

Encl: as above

Annexure I

Sl. No.	Particulars	Details
1	Name(s) of parties with whom the agreement is entered	<p>Biocon Limited, a company incorporated under the Companies Act, 2013, and having corporate identification number L24234KA1978PLC003417; and</p> <p>Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 (Seller 1); and Goldman Sachs India AIF Scheme-1 (Seller 2), schemes setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited.</p>
2	Purpose of entering into the agreement	<p>The parties have entered into an agreement whereby the Company shall purchase 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) of Biocon Biologics Limited, an unlisted subsidiary of the Company, of face value of Rs. 1,00,00,000 each for a consideration of INR equivalent to USD 198.50 Million, (which may be varied depending on the date of purchase) as follows:</p> <ul style="list-style-type: none"> ➤ 1,047 OCDs from Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 (Seller 1); and ➤ 78 OCDs from Goldman Sachs India AIF Scheme-1 (Seller 2).
3	Shareholding, if any, in the entity with whom the agreement is executed	NIL.
4	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	The Company shall purchase 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) of Biocon Biologics Limited, an unlisted subsidiary of the Company, of face value of Rs. 1,00,00,000 each for a consideration of INR equivalent to USD 198.50 Million, which may be varied depending on the date of purchase.
5	Whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	Not Applicable.
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Not Applicable.
7	In case of issuance of shares to the parties, details of issue price, class of shares issued.	Not Applicable.
8	Any other disclosures related to such agreements, viz., details of nominee on the board	Not Applicable.

Sl. No.	Particulars	Details
	of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	
9	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable.